Mirum Pharmaceuticals, Inc. MIRM Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Mirum Pharmaceuticals, Inc. (MIRM) reported business segments — operating income (loss) of -$789.47M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s business segments — operating income (loss) changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s business segments — operating income (loss) decreased by 5099.7% year-over-year, from -$15.18M to -$789.47M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Mirum Pharmaceuticals, Inc.'s business segments — operating income (loss) has grown at a -44.7% compound annual growth rate (CAGR), from -$131.22M to -$22.14M.
- What does business segments — operating income (loss) mean?
- Calculated as total revenue minus operating expenses, this metric represents the core profitability of the business segment before interest and taxes. It serves as a primary indicator of the company's ability to generate sustainable earnings from its commercial and development activities.